Biodesix Inc Stock News

One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented

Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients

LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company's common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company's common stock w...

LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference on Thursday, September 11, 2025.

Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer Biodesix recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer

Biodesix, Inc. (NASDAQ:BDSX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Robin Harper Cowie - CFO, Secretary & Treasurer Scott Hutton - President, CEO & Director Conference Call Participants Alexander Davis Vukasin - Canaccord Genuity Corp., Research Division Andrew Frederick Brackmann - William Blair & Company L.L.C., Research Division Thomas Flaten - Lake ...

Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.

BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.